Tetracycline antibiotics: Potential anticancer drugs

Synthesis of Isosteviol derivatives as potential anticancer agents, especially for ovarian Cancer: In vitro cytotoxicity, cell cycle arrest, network pharmacology and molecular docking study

Isosteviol is a tetracyclic diterpenoid from the hydrolysis of steviosidic acid, it exhibits a moderate inhibitory impact on tumor proliferation across various cancer types. Herein, we improved antitumor efficacy of isosteviol by modifying its reactive groups at C-16 and C-19 positions. A series of isosteviol derivatives 2-17, were synthesized and characterized. Their anti-proliferative activities were evaluated in three human cancer cell lines (HCT116, SKOV3 and HepG2) by CCK-8 assay. The results showed that derivative 10 has strong cancer cell inhibitory activities (with IC50 = 24.98 ± 1.82 μM for HCT116, IC50 = 26.15 ± 0.05 μM for SKOV3 and IC50 = 23.09 ± 0.31 μM for HepG2 cells). Accordingly, structure-activity relationships (SARs) of these isosteviol derivatives in ovarian cancer SKOV3 cells were discussed in detail. Moreover, derivative 10 has concentration-dependent cell cycle arrest at S-G2/M phases in SKOV3 cells, and it could greatly induce apoptosis. In addition, the targets of isosteviol against ovarian cancer were predicted and analyzed via network pharmacology. Then, molecular docking analysis showed that derivative 10 could interact with HSP90AA1 through its LYS-58 residues (docking energy: -8.96 kal/mol). The results suggested that derivative 10 might be employed as a promising drug candidate for anticancer chemotherapy.

Antagonistic effects of polystyrene microplastics and tetracycline on Chlorella pyrenoidosa as revealed by infrared spectroscopy coupled with multivariate analysis

Microplastics and antibiotics are typical emerging contaminants in the environment, posing considerable risks to the ecosystem and human health. Previous studies have reported synergistic or antagonistic effects in the presence of both microplastics and antibiotics, destructing cell membrane, inhibiting photosynthetic capability, and inducing antioxidant enzyme activity. However, there is still lack of comprehensive understanding of the mechanisms. This study applied infrared biospectroscopy and multivariate analysis to explore the physiological and biochemical toxicity of polystyrene microplastics and tetracycline co-exposure on Chlorella pyrenoidosa. Either tetracycline or polystyrene microplastics alone posed toxicities on C. pyrenoidosa, mainly due to changes in photosynthetic content, cell membrane permeability, MDA content and antioxidant enzyme activity. Co-exposure of tetracycline and polystyrene microplastics exhibited an antagonistic effect. Infrared spectroscopy coupled with multivariate analysis isolated the discriminating biomarkers representing different toxicity mechanisms, successfully explaining the mechanism of antagonism as reducing ROS production, regulating antioxidant enzyme activity, stabilizing cell membrane, and interfering with signaling and protein synthesis. A random forest model was developed and satisfactorily recognized the toxicity of individual toxins (accuracy of 98.75 %, sensitivity of 99.22 % and specificity of 99.65 %). It also rapidly apportioned toxicity origin and evidenced that tetracycline contributed to the majority of binary toxicities. This study provided scientific guidance and a theoretical basis for assessing and apportioning the binary toxicities of emerging contaminants.

Doxycycline: An essential tool for Alzheimer's disease

The identification of active interventions in neurodegenerative disorders is a major challenge in neurology; the use of repurposed drugs may represent a valuable strategy. Tetracyclines, a second generation of antibiotic molecules, offer various potential applications. Following an anecdotal observation of the potential anti-amyloidogenic activity of iododoxorubicin, the search for chemical analogs with a better safety profile led to tetracyclines. Their heterocyclic structures with a planar conformation interfere with b-sheet amyloid formation. Thus, doxycycline, a derivative with favorable blood-brain barrier penetration, emerged as a strong candidate to combat peripheral and central amyloidosis. In particular, we tested the anti-prion activity of doxycycline in vitro and in vivo experiments, confirming its capacity to disrupt or inhibit the formation of prion protein aggregates associated with pathological events. Treatment with doxycycline in human subjects with prion - related encephalopathies yielded contradictory results, suggesting that a preventive approach is a more favorable condition to verify efficacy; a clinical trial involving subjects at genetic risk of developing fatal familial insomnia, exposed to doxycycline for ten years, is currently ongoing. The anti-amyloidogenic capacity of doxycycline, combined with its safety profile in long-term treatment, has suggested its use in peripheral amyloidosis, which was tested with positive results. A specific interaction with β-amyloid or α-synuclein oligomers, as well as tau aggregation has also been demonstrated. More recently, the action of doxycycline has been extended to its anti-inflammatory and antioxidant capacities. In particular, the anti-inflammatory activity of doxycycline may explain the drug 's efficacy in numerous experimental models where protein misfolding has been associated with neuroinflammation, including Huntington's and Parkinson' s diseases. Thus, the pleiotropic action of doxycycline appears to be an interesting tool for addressing progressive neuronal dysfunction in multifactorial neurodegenerative diseases. The application of precision medicine principles to doxycycline treatment represents the best strategy to determine its efficacy. These aspects are illustrated here concerning another pleiotropic tetracycline, minocycline.

(Bio)Electroanalysis of Tetracyclines: Recent Developments

Tetracyclines (TCs) are antibiotics used extensively in medicine, veterinary science, and animal husbandry. Their overuse and the widespread presence of their residues in the environment contribute to intensifying the phenomenon of antibiotic resistance (ABR). The efforts are being made to reduce the spread of antibiotics and control the phenomenon of ABR, and one of the key methods is monitoring the presence of antibiotic residues in the environment and food of animal origin. Herein, we provide the overview of the recent developments in electrochemical (bio)sensing of tetracyclines in different types of samples. The review presents a comprehensive view of such aspects of the practical (bio)sensor application as sample preparation, the reusability of (bio)sensors, and the possibility of determining antibiotics at levels required by regulations. Advances, existing challenges, and future trends in the development of novel (bio)electrochemical methods of tetracycline quantification were discussed.

A smartphone-integrated bimetallic ratiometric fluorescent probe for specific visual detection of tetracycline antibiotics in food samples and latent fingerprinting

Designing and preparing highly sensitive and accurate fluorescent chemosensors for monitoring tetracycline antibiotics remains a challenge. Herein, a fluorescent chemosensor based on lanthanide metal-organic frameworks (Ln-MOFs) is proposed to realize high-precision monitoring by adjusting the ratio of lanthanide ions. Ln-MOFs with good aqueous stability were prepared by a solvothermal method using Eu3+, Tb3+ and the ligand 4,4',4″-s-triazine-2,4,6-triyltribenzoic acid (H3TATB) in DMF/NMP/H2O. The Ln-MOFs could recognize oxytetracycline (OTC) and doxycycline (DOX), and the detection limits of OTC and DOX were as low as 8.6 and 4.8 nM, respectively. In particular, Eu(1.4 μM)-Tb-MOF sensors were used for visual detection of OTC and DOX in combination with smartphones with detection lines as low as 9.8 nM and 14.2 nM, respectively. Meanwhile, Eu-MOF, Tb-MOF and Eu(1.4 μM)-Tb-MOF can be used for latent fingerprint (LFP) visualization, demonstrating their potential applications in the field of criminal case investigation. The developed probes were successfully applied to determining OTC and DOX in milk, beef and pork with recoveries ranging from 92.0 % to 109.63 % and relative standard deviations (RSDs) ranging from 1.83 % to 4.56 %. Eu(1.4 μM)-Tb-MOF is believed to utilize its lanthanide metal ion coordination and photoinduced electron transfer (PET) mechanism to achieve highly selective and accurate OTC and DOX detection, which is supported by experimental and density functional theory (DFT) calculations.

Unraveling the Anti-Cancer Mechanisms of Antibiotics: Current Insights, Controversies, and Future Perspectives

Cancer persists as a significant global health challenge, claiming millions of lives annually despite remarkable strides in therapeutic innovation. Challenges such as drug resistance, toxicity, and suboptimal efficacy underscore the need for novel treatment paradigms. In this context, the repurposing of antibiotics as anti-cancer agents has emerged as an attractive prospect for investigation. Diverse classes of antibiotics have exhibited promising anti-cancer properties in both in vitro and in vivo studies. These mechanisms include the induction of apoptosis and cell cycle arrest, generation of reactive oxygen species, and inhibition of key regulators of cell proliferation and migration. Additional effects involve the disruption of angiogenesis and modulation of pivotal processes such as inflammation, immune response, mitochondrial dynamics, ferroptosis, and autophagy. Furthermore, antibiotics have demonstrated the potential to enhance the efficacy of conventional modalities like chemotherapy and radiotherapy, while alleviating treatment-induced toxicities. Nevertheless, the integration of antibiotics into oncological applications remains contentious, with concerns centered on their disruption of gut microbiota, interference with immunotherapeutic strategies, contribution to microbial resistance, and potential association with tumorigenesis. This narrative review explores the mechanisms of antibiotics' anti-cancer activity, addresses controversies about their dual role in cancer biology, and envisions future perspectives that include the development of novel derivatives and innovative frameworks for their incorporation into cancer treatment paradigms.

Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets

The mitochondrion is an essential cell organelle known as the powerhouse of the cell. Mitochondrial ribosomal proteins (MRPs) are nuclear encoded, synthesised in the cytoplasm but perform their main functions in the mitochondria, which includes translation, transcription, cell death and maintenance. However, MRPs have also been implicated in cancer, particularly advanced disease and metastasis across a broad range of cancer types, where they play a central role in cell survival and progression. For some, their altered expression has been investigated as potential prognostic markers, and/or therapeutic targets, which is the focus of this review. Several therapies targeting MRPs are currently approved by the Food and Drug Administration and the European Medicines Agency for use in other diseases, revealing the opportunity for repurposing their use in advanced and metastatic cancer. Herein, we review the evidence supporting key MRPs as molecular drivers of advanced disease in multiple cancer types. We also highlight promising avenues for future use of MRPs as precision targets in the treatment of late-stage cancers for which there are currently very limited effective treatment options.

Drug Repurposing for Cancer Treatment: A Comprehensive Review

Cancer ranks among the primary contributors to global mortality. In 2022, the global incidence of new cancer cases reached about 20 million, while the number of cancer-related fatalities reached 9.7 million. In Saudi Arabia, there were 13,399 deaths caused by cancer and 28,113 newly diagnosed cases of cancer. Drug repurposing is a drug discovery strategy that has gained special attention and implementation to enhance the process of drug development due to its time- and money-saving effect. It involves repositioning existing medications to new clinical applications. Cancer treatment is a therapeutic area where drug repurposing has shown the most prominent impact. This review presents a compilation of medications that have been repurposed for the treatment of various types of cancers. It describes the initial therapeutic and pharmacological classes of the repurposed drugs and their new applications and mechanisms of action in cancer treatment. The review reports on drugs from various pharmacological classes that have been successfully repurposed for cancer treatment, including approved ones and those in clinical trials and preclinical development. It stratifies drugs based on their anticancer repurpose as multi-type, type-specific, and mechanism-directed, and according to their pharmacological classes. The review also reflects on the future potential that drug repurposing has in the clinical development of novel anticancer therapies.

High-throughput drug screening using a library of antibiotics targeting cancer cell lines that are resistant and sensitive to gemcitabine

Gemcitabine is a nucleoside analog widely used as an anticancer agent against several types of cancer. Although gemcitabine sometimes shows excellent effectiveness, cancer cells are often poorly responsive to or resistant to the drug. Recently, specific strains or dysbiosis of the human microbiome were correlated with drug reactivity and resistance acquisition. Therefore, we aimed to identify antibiotic compounds that can modulate the microbiome to enhance the responsiveness to gemcitabine. To achieve this, we confirmed the gemcitabine responsiveness based on public data and conducted drug screening on a set of 250 antibiotics compounds. Subsequently, we performed experiments to investigate whether the selected compounds could enhance the responsiveness to gemcitabine. First, we grouped a total of seven tumor cell lines into resistant and sensitive group based on the IC50 value (1 μM) of gemcitabine obtained from the public data. Second, we performed high-throughput screening with compound treatments, identifying seven compounds from the resistant group and five from the sensitive group based on dose dependency. Finally, the combination of the selected compound, puromycin dihydrochloride, with gemcitabine in gemcitabine-resistant cell lines resulted in extensive cell death and a significant increase in cytotoxic efficacy. Additionally, mRNA levels associated with cell viability and stemness were reduced. Through this study, we screened antibiotics to further improve the efficacy of existing anticancer drugs and overcome resistance. By combining existing anticancer agents and antibiotic substances, we hope to establish various drug combination therapies and ultimately improve cancer treatment efficacy.

Metagenomic evidence for antibiotic-associated actinomycetes in the Karamay Gobi region

Due to the misuse of antibiotics, there is an increasing emergence and spread of multidrug-resistant (MDR) bacteria, leading to a human health crisis. To address clinical antibiotic resistance and prevent/control pathogenic microorganisms, the development of novel antibiotics is essential. This also offers a new approach to discovering valuable actinobacterial flora capable of producing natural bioactive products. In this study, we employed bioinformatics and macro-genome sequencing to collect 15 soil samples from three different locations in the Karamay Gobi region. First, we assessed the diversity of microorganisms in soil samples from different locations, analyzing the content of bacteria, archaea, actinomycetes, and fungi. The biodiversity of soil samples from outside the Gobi was found to be higher than that of soil samples from within and in the center of the Gobi. Second, through microbial interaction network analysis, we identified actinomycetes as the dominant group in the system. We have identified the top four antibiotic genes, such as Ecol_fabG_TRC, Efac_liaR_DAP, tetA (58), and macB, by CARD. These genes are associated with peptide antibiotics, disinfecting agents and antiseptics, tetracycline antibiotics, and macrolide antibiotics. In addition, we also obtained 40 other antibiotic-related genes through CARD alignment. Through in-depth analysis of desert soil samples, we identified several unstudied microbial species belonging to different families, including Erythrobacteriaceae, Solirubrobacterales, Thermoleophilaceae, Gaiellaceae, Nocardioidaceae, Actinomycetia, Egibacteraceae, and Acidimicrobiales. These species have the capability to produce peptide antibiotics, macrolide antibiotics, and tetracycline antibiotics, as well as disinfectants and preservatives. This study provides valuable theoretical support for future in-depth research.

Tetracycline removal from soil by phosphate-modified biochar: Performance and bacterial community evolution

Since the remediation performance of soil tetracycline pollution by original biochar is not ideal, many modified methods have been proposed to improve its performance. Considering the cost, complex modification process and environmental friendliness, many modified biochar are difficult to be used in soil environments. In this work, biochar derived from corn stover was modified using phosphate to increase the adsorption ability of soil tetracycline and alleviate the negative effects caused by tetracycline. The results showed that pyrolysis temperatures and anion types of phosphate (PO43-, HPO42-, H2PO4-) played important roles in the performance of modified biochar. Compared with original biochar, phosphate modified biochar not only improved the adsorption capacity, but also changed the adsorption behavior of tetracycline. Via SEM, BET and FTIR techniques, the intrinsic reasons for the increase of adsorption capacity were explained by the change of morphological structures as well as functional groups of the modified biochar. K3PO4 and high temperature (800 °C) maximally improved the surface morphology, increased the pore structure, changed the surface functional groups of biochar, and then increased the adsorption capacity of tetracycline (124.51 mg/g). Subsequently, the optimal material (K3PO4-800) was selected and applied for tetracycline contaminated soil remediation. Compared to the soil without remediation, K3PO4-800 modified biochar effectively reduced the effective concentration of tetracycline in soil, and improved soil K and P nutrition, and reshaped microbial communities. Our study showed that K3PO4-800 modified biochar was not only a good tetracycline resistant material, but also a good soil amendment.

The combination of tetracyclines effectively ameliorates liver fibrosis via inhibition of EphB1/2

Eph receptor tyrosine kinase EphB1/2 contributes to the development of liver fibrosis, suggesting the rationale that EphB1/2 inhibitors may be effective in liver fibrosis therapy. Since tetracycline antibiotics were recently demonstrated as EphB kinase inhibitors, in present study we investigated their therapeutic potential against liver fibrosis. Our results showed that the tetracycline combination of demeclocycline (D), chlortetracycline (C), and minocycline (M) inhibited the activation of hepatic stellate cells (HSCs) in vitro and alleviated CCl4-induced animal model of liver fibrosis in vivo. Mechanistically, DCM combination inhibited EphB1/2 phosphorylation and subsequent activation of the MAPK signaling. Moreover, we found that short-term and low-dose DCM combination treatment decreased tissue inflammation and improved liver fibrosis in mice. Thus, our study indicates that tetracyclines may be repurposed for the treatment of liver fibrosis.